Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in aml1-eto – positive acute myeloid leukemia

HIGHLIGHTS

• who: -drug combination and colleagues from the Southwest Jiaotong University, China have published the article: Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in AML1-ETO - positive acute myeloid leukemia, in the Journal: (JOURNAL)
• what: The authors sought to explore the safety and efficacy of the combined regimen for AML1-ETO patients with molecular relapse post transplantation.
• how: The results showed that the median overall survival and event-free survival were 10.3 and 6.1 months after HSCT2 respectively and acute GVHD cases numbered as high as 28 (35 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.